XERAD: Open-label, Phase II, Randomized, Comparative, Multicentre Trial of Concurrent Whole Brain Radiation Therapy (WBRT) and Capecitabine (Xeloda) Followed by Maintenance Capecitabine Compared With Standard WBRT in Breast Cancer Patients With Newly Diagnosed Brain Metastasis

Trial Profile

XERAD: Open-label, Phase II, Randomized, Comparative, Multicentre Trial of Concurrent Whole Brain Radiation Therapy (WBRT) and Capecitabine (Xeloda) Followed by Maintenance Capecitabine Compared With Standard WBRT in Breast Cancer Patients With Newly Diagnosed Brain Metastasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Capecitabine (Primary) ; Antineoplastics
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms XERAD
  • Sponsors Roche
  • Most Recent Events

    • 26 Sep 2016 Status changed from completed to discontinued Due to an insufficient number of participants enrolled.
    • 15 Nov 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 15 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top